Elaine Setiawan1, Alan A Wilson2, Romina Mizrahi2, Pablo M Rusjan1, Laura Miler1, Grazyna Rajkowska3, Ivonne Suridjan4, James L Kennedy2, P Vivien Rekkas1, Sylvain Houle2, Jeffrey H Meyer2. 1. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada2Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. 2. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada2Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada3Department of Psychiatry, University of Toronto, T. 3. Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson. 4. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada2Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada4Institute of Medical Science, University of Toront.
Abstract
IMPORTANCE: The neuroinflammatory hypothesis of major depressive disorder is supported by several main findings. First, in humans and animals, activation of the immune system causes sickness behaviors that present during a major depressive episode (MDE), such as low mood, anhedonia, anorexia, and weight loss. Second, peripheral markers of inflammation are frequently reported in major depressive disorder. Third, neuroinflammatory illnesses are associated with high rates of MDEs. However, a fundamental limitation of the neuroinflammatory hypothesis is a paucity of evidence of brain inflammation during MDE. Translocator protein density measured by distribution volume (TSPO VT) is increased in activated microglia, an important aspect of neuroinflammation. OBJECTIVE: To determine whether TSPO VT is elevated in the prefrontal cortex, anterior cingulate cortex (ACC), and insula in patients with MDE secondary to major depressive disorder. DESIGN, SETTING, AND PARTICIPANTS: Case-control study in a tertiary care psychiatric hospital from May 1, 2010, through February 1, 2014. Twenty patients with MDE secondary to major depressive disorder and 20 healthy control participants underwent positron emission tomography with fluorine F 18-labeled N-(2-(2-fluoroethoxy)benzyl)-N-(4-phenoxypyridin-3-yl)acetamide ([18F]FEPPA). Patients with MDE were medication free for at least 6 weeks. All participants were otherwise healthy and nonsmokers. MAIN OUTCOMES AND MEASURES: Values of TSPO VT in the prefrontal cortex, ACC, and insula. RESULTS: In MDE, TSPO VT was significantly elevated in all brain regions examined (multivariate analysis of variance, F15,23 = 4.5 [P = .001]). The magnitude of TSPO VT elevation was 26% in the prefrontal cortex (mean [SD] TSPO VT, 12.5 [3.6] in patients with MDE and 10.0 [2.4] in controls), 32% in the ACC (mean [SD] TSPO VT, 12.3 [3.5] in patients with MDE and 9.3 [2.2] in controls), and 33% in the insula (mean [SD] TSPO VT, 12.9 [3.7] in patients with MDE and 9.7 [2.3] in controls). In MDE, greater TSPO VT in the ACC correlated with greater depression severity (r = 0.63 [P = .005]). CONCLUSIONS AND RELEVANCE: This finding provides the most compelling evidence to date of brain inflammation, and more specifically microglial activation, in MDE. This finding is important for improving treatment because it implies that therapeutics that reduce microglial activation should be promising for MDE. The correlation between higher ACC TSPO VT and the severity of MDE is consistent with the concept that neuroinflammation in specific regions may contribute to sickness behaviors that overlap with the symptoms of MDE.
IMPORTANCE: The neuroinflammatory hypothesis of major depressive disorder is supported by several main findings. First, in humans and animals, activation of the immune system causes sickness behaviors that present during a major depressive episode (MDE), such as low mood, anhedonia, anorexia, and weight loss. Second, peripheral markers of inflammation are frequently reported in major depressive disorder. Third, neuroinflammatory illnesses are associated with high rates of MDEs. However, a fundamental limitation of the neuroinflammatory hypothesis is a paucity of evidence of brain inflammation during MDE. Translocator protein density measured by distribution volume (TSPOVT) is increased in activated microglia, an important aspect of neuroinflammation. OBJECTIVE: To determine whether TSPOVT is elevated in the prefrontal cortex, anterior cingulate cortex (ACC), and insula in patients with MDE secondary to major depressive disorder. DESIGN, SETTING, AND PARTICIPANTS: Case-control study in a tertiary care psychiatric hospital from May 1, 2010, through February 1, 2014. Twenty patients with MDE secondary to major depressive disorder and 20 healthy control participants underwent positron emission tomography with fluorine F 18-labeled N-(2-(2-fluoroethoxy)benzyl)-N-(4-phenoxypyridin-3-yl)acetamide ([18F]FEPPA). Patients with MDE were medication free for at least 6 weeks. All participants were otherwise healthy and nonsmokers. MAIN OUTCOMES AND MEASURES: Values of TSPOVT in the prefrontal cortex, ACC, and insula. RESULTS: In MDE, TSPOVT was significantly elevated in all brain regions examined (multivariate analysis of variance, F15,23 = 4.5 [P = .001]). The magnitude of TSPOVT elevation was 26% in the prefrontal cortex (mean [SD] TSPOVT, 12.5 [3.6] in patients with MDE and 10.0 [2.4] in controls), 32% in the ACC (mean [SD] TSPOVT, 12.3 [3.5] in patients with MDE and 9.3 [2.2] in controls), and 33% in the insula (mean [SD] TSPOVT, 12.9 [3.7] in patients with MDE and 9.7 [2.3] in controls). In MDE, greater TSPOVT in the ACC correlated with greater depression severity (r = 0.63 [P = .005]). CONCLUSIONS AND RELEVANCE: This finding provides the most compelling evidence to date of brain inflammation, and more specifically microglial activation, in MDE. This finding is important for improving treatment because it implies that therapeutics that reduce microglial activation should be promising for MDE. The correlation between higher ACC TSPOVT and the severity of MDE is consistent with the concept that neuroinflammation in specific regions may contribute to sickness behaviors that overlap with the symptoms of MDE.
Authors: Johann Steiner; Hendrik Bielau; Ralf Brisch; Peter Danos; Oliver Ullrich; Christian Mawrin; Hans-Gert Bernstein; Bernhard Bogerts Journal: J Psychiatr Res Date: 2006-12-15 Impact factor: 4.791
Authors: Rainer Rupprecht; Vassilios Papadopoulos; Gerhard Rammes; Thomas C Baghai; Jinjiang Fan; Nagaraju Akula; Ghislaine Groyer; David Adams; Michael Schumacher Journal: Nat Rev Drug Discov Date: 2010-12 Impact factor: 84.694
Authors: Ghanshyam N Pandey; Hooriyah S Rizavi; Xinguo Ren; Jawed Fareed; Debra A Hoppensteadt; Rosalinda C Roberts; Robert R Conley; Yogesh Dwivedi Journal: J Psychiatr Res Date: 2011-09-08 Impact factor: 4.791
Authors: Johann Steiner; Martin Walter; Tomasz Gos; Gilles J Guillemin; Hans-Gert Bernstein; Zoltán Sarnyai; Christian Mawrin; Ralf Brisch; Hendrik Bielau; Louise Meyer zu Schwabedissen; Bernhard Bogerts; Aye-Mu Myint Journal: J Neuroinflammation Date: 2011-08-10 Impact factor: 8.322
Authors: Neil A Harrison; Lena Brydon; Cicely Walker; Marcus A Gray; Andrew Steptoe; Hugo D Critchley Journal: Biol Psychiatry Date: 2009-05-07 Impact factor: 13.382
Authors: Sara Bromander; Rolf Anckarsäter; Marianne Kristiansson; Kaj Blennow; Henrik Zetterberg; Henrik Anckarsäter; Caroline E Wass Journal: J Neuroinflammation Date: 2012-10-24 Impact factor: 8.322
Authors: Christine M Sandiego; Jean-Dominique Gallezot; Brian Pittman; Nabeel Nabulsi; Keunpoong Lim; Shu-Fei Lin; David Matuskey; Jae-Yun Lee; Kevin C O'Connor; Yiyun Huang; Richard E Carson; Jonas Hannestad; Kelly P Cosgrove Journal: Proc Natl Acad Sci U S A Date: 2015-09-18 Impact factor: 11.205
Authors: Christopher A Lowry; David G Smith; Philip H Siebler; Dominic Schmidt; Christopher E Stamper; James E Hassell; Paula S Yamashita; James H Fox; Stefan O Reber; Lisa A Brenner; Andrew J Hoisington; Teodor T Postolache; Kerry A Kinney; Dante Marciani; Mark Hernandez; Sian M J Hemmings; Stefanie Malan-Muller; Kenneth P Wright; Rob Knight; Charles L Raison; Graham A W Rook Journal: Curr Environ Health Rep Date: 2016-09
Authors: Sophia Attwells; Elaine Setiawan; Alan A Wilson; Pablo M Rusjan; Romina Mizrahi; Laura Miler; Cynthia Xu; Margaret Anne Richter; Alan Kahn; Stephen J Kish; Sylvain Houle; Lakshmi Ravindran; Jeffrey H Meyer Journal: JAMA Psychiatry Date: 2017-08-01 Impact factor: 21.596
Authors: Daisuke Fukudome; Lindsay N Hayes; Travis E Faust; Catherine A Foss; Mari A Kondo; Brian J Lee; Atsushi Saito; Shin-Ichi Kano; Jennifer M Coughlin; Atsushi Kamiya; Martin G Pomper; Akira Sawa; Minae Niwa Journal: Schizophr Res Date: 2018-02-03 Impact factor: 4.939
Authors: Neydher Berroterán-Infante; Theresa Balber; Petra Fürlinger; Michael Bergmann; Rupert Lanzenberger; Marcus Hacker; Markus Mitterhauser; Wolfgang Wadsak Journal: ACS Med Chem Lett Date: 2018-02-21 Impact factor: 4.345